含的可生物降解的多孔微球用于凝血病的血液静止
Ruiying Kou1, Yunpeng Wang1, Jing Li1
1National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China. bhe@scu.edu.cn.
Journal of materials chemistry. B
|April 3, 2025
概括
新的生物降解微球有效地阻止了凝血病患者的出血. 这些带的多孔微球 (CPBM) 加快凝血,在动物模型中优于现有的静血剂.
科学领域:
- 生物材料科学 生物材料科学
- 血液静止研究 血液静止研究
- 聚合物化学 聚合物化学
背景情况:
- 凝血障碍对有效的血液静止构成重大挑战.
- 开发先进的静血材料对于治疗凝血病患者的出血至关重要.
研究的目的:
- 开发和评估可生物降解的多孔微球,以改善凝血病状况下的血静.
- 在临床前模型中研究离子载荷微球 (CPBM) 的静血效果.
主要方法:
- 制造多块两性聚氨 (PCGA/PEG) 成为多孔微球.
- 通过溶液浸泡将离子载入微球.
- 在体外评估吸水,离子释放和促凝活性 (血小板聚合,红细胞粘附,纤维素形成).
- 在大鼠肝损伤和尾巴截肢模型中静血性能的体内评估.
主要成果:
- 微球呈现出高孔隙度,均尺寸和优异的生物相容性.
- CPBMs显示了超高的吸水率 (45x) 和快速的离子释放.
- 观察到显著促进血小板聚合,红细胞粘附和纤维素形成.
- 与商业药物 (BT,YB) 相比,CPBM在健康和凝血病老鼠中表现出优异的血液静止.
结论:
- 装有离子的可生物降解的多孔微球代表了一个有前途的先进的静血材料.
- CPBMs有效地加速凝血级联,并提供优质的血液静止.
- 这些发现表明,在患有凝血障碍的患者中管理出血的潜在临床应用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
Introduction to Hemostasis
4.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.5K
Extrinsic and Intrinsic Pathways of Hemostasis
4.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.2K
Coagulation
3.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.8K


